PharmaShots | Incisive News in 3 Shots

Subscribe Now

Chiesi Global Rare Diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receives the US FDA’s Approval of Elfabrio (pegunigalsidase alfa-iwxj) for Fabry Disease

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receives the US FDA’s Approval of Elfabrio (pegunigalsidase alfa-iwxj) fo...

May 10, 2023

PharmaShots Weekly Snapshots (May 01 - 05, 2023)

PharmaShots Weekly Snapshots (May 01 - 05, 2023)

May 5, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) fo...

May 5, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EMA’s CHMP Positive Opinion of Pegunigalsidase Alfa for Fabry Disease

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EMA’s CHMP Positive Opinion of Pegunigalsidase Alfa for Fabry Dis...

March 20, 2023

Chiesi Global Rare Diseases Receives the US FDA’s Approval of Lamzede (velmanase alfa-tycv) for Alpha-Mannosidosis

Chiesi Global Rare Diseases Receives the US FDA’s Approval of Lamzede (velmanase alfa-tycv) for Alpha-Mannosidosis

February 16, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us